These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22102708)

  • 41. Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.
    Hasan S; Cassinat B; Droin N; Le Couedic JP; Favale F; Monte-Mor B; Lacout C; Fontenay M; Dosquet C; Chomienne C; Solary E; Villeval JL; Casadevall N; Kiladjian JJ; Vainchenker W; Plo I
    Leukemia; 2014 Feb; 28(2):460-3. PubMed ID: 24150219
    [No Abstract]   [Full Text] [Related]  

  • 42.
    Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
    Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two clinical phenotypes in polycythemia vera.
    Spivak JL; Considine M; Williams DM; Talbot CC; Rogers O; Moliterno AR; Jie C; Ochs MF
    N Engl J Med; 2014 Aug; 371(9):808-17. PubMed ID: 25162887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
    Leszczynska A; Grzenkowicz-Wydra J; Chmielewska-Gorycka L; Bieniaszewska M; Hellmann A
    Acta Haematol; 2016; 136(2):123-8. PubMed ID: 27410038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
    Zhang ZR; Duan YC
    Asian Pac J Cancer Prev; 2014; 15(4):1681-4. PubMed ID: 24641389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
    Karkucak M; Yakut T; Ozkocaman V; Ozkalemkas F; Ali R; Bayram M; Gorukmez O; Ocakoglu G
    Mol Biol Rep; 2012 Sep; 39(9):8663-7. PubMed ID: 22722988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.
    Veneri D; Capuzzo E; de Matteis G; Franchini M; Baritono E; Benati M; Solero GP; Ambrosetti A; Quaresmini G; Pizzolo G
    Blood Transfus; 2009 Jul; 7(3):204-9. PubMed ID: 19657484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polycythemia vera: the current status of preclinical models and therapeutic targets.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
    Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
    Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
    Albizua E; Gallardo M; Barrio S; Rapado I; Jimenez A; Ayala R; Rueda D; Sanchez-Espiridion B; Puigdecanet E; Espinet B; Florensa L; Besses C; Martinez-Lopez J
    Ann Hematol; 2011 Aug; 90(8):939-46. PubMed ID: 21331593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
    Williams DM; Kim AH; Rogers O; Spivak JL; Moliterno AR
    Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.
    Shimoda K; Qin A; Komatsu N; Kirito K
    Int J Hematol; 2024 Aug; 120(2):151-156. PubMed ID: 38951434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
    Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
    Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency of Janus associated kinase 2 (V617F) mutation in patients of polycythemia vera.
    Khattak SA; Ahmed S; Anwar J; Bozdar M
    J Coll Physicians Surg Pak; 2012 Feb; 22(2):80-3. PubMed ID: 22313642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings.
    Ferdowsi S; Atarodi K; Amirizadeh N; Toogeh G; Azarkeivan A; Shirkoohi R; Faranoush M; Vaezi M; Alimoghaddam K; Ghavamzadeh A; Naghadeh HT; Ghaffari SH
    Int J Lab Hematol; 2015 Oct; 37(5):661-7. PubMed ID: 26011312
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 59. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
    Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
    Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.
    Swierczek SI; Yoon D; Bellanné-Chantelot C; Kim SJ; Saint-Martin C; Delhommeau F; Najman A; Prchal JT
    Haematologica; 2011 May; 96(5):775-8. PubMed ID: 21273266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.